Literature DB >> 24505618

Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy.

Wen Zhou, Joyce M Slingerland.   

Abstract

Oestrogen receptor-α (ERα) is a master transcription factor that regulates cell proliferation and homeostasis in many tissues. Despite beneficial ERα functions, sustained oestrogenic exposure increases the risk and/or the progression of various cancers, including those of the breast, endometrium and ovary. Oestrogen–ERα interaction can trigger post-translational ERα modifications through crosstalk with signalling pathways to promote transcriptional activation and ubiquitin-mediated ERα proteolysis, with co-activators that have dual roles as ubiquitin ligases. These processes are reviewed herein. The elucidation of mechanisms whereby oestrogen drives both ERα transactivation and receptor proteolysis might have important therapeutic implications not only for breast cancer but also potentially for other hormone-regulated cancers.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24505618     DOI: 10.1038/nrc3622

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  182 in total

1.  BRCA1 inhibition of estrogen receptor signaling in transfected cells.

Authors:  S Fan; J Wang; R Yuan; Y Ma; Q Meng; M R Erdos; R G Pestell; F Yuan; K J Auborn; I D Goldberg; E M Rosen
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

2.  Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen receptor alpha N terminus.

Authors:  Christopher C Valley; Raphaël Métivier; Natalia M Solodin; Amy M Fowler; Mara T Mashek; Lindsay Hill; Elaine T Alarid
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

Review 3.  17beta-estradiol signaling in skeletal muscle cells and its relationship to apoptosis.

Authors:  Ricardo Boland; Andrea Vasconsuelo; Lorena Milanesi; Ana C Ronda; Ana R de Boland
Journal:  Steroids       Date:  2008-01-04       Impact factor: 2.668

Review 4.  Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation.

Authors:  David M Lonard; Bert W O'malley
Journal:  Mol Cell       Date:  2007-09-07       Impact factor: 17.970

5.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

6.  Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation.

Authors:  Robert X-D Song; Robert A McPherson; Liana Adam; Yongde Bao; Margaret Shupnik; Rakesh Kumar; Richard J Santen
Journal:  Mol Endocrinol       Date:  2002-01

7.  The ubiquitin-conjugating enzyme UBCH7 acts as a coactivator for steroid hormone receptors.

Authors:  Seema Verma; Ayesha Ismail; Xiuhua Gao; Guilian Fu; Xiaotao Li; Bert W O'Malley; Zafar Nawaz
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

8.  Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer.

Authors:  Isabel Chu; Angel Arnaout; Sophie Loiseau; Jun Sun; Arun Seth; Chris McMahon; Kathy Chun; Bryan Hennessy; Gordon B Mills; Zafar Nawaz; Joyce M Slingerland
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

9.  Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase.

Authors:  S Kato; H Endoh; Y Masuhiro; T Kitamoto; S Uchiyama; H Sasaki; S Masushige; Y Gotoh; E Nishida; H Kawashima; D Metzger; P Chambon
Journal:  Science       Date:  1995-12-01       Impact factor: 47.728

10.  Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.

Authors:  Alison M Hosey; Julia J Gorski; Margaret M Murray; Jennifer E Quinn; Wen Y Chung; Gail E Stewart; Colin R James; Susan M Farragher; Jude M Mulligan; Alistair N Scott; Peter A Dervan; Patrick G Johnston; Fergus J Couch; Peter A Daly; Elaine Kay; Amanda McCann; Paul B Mullan; D Paul Harkin
Journal:  J Natl Cancer Inst       Date:  2007-11-13       Impact factor: 13.506

View more
  64 in total

1.  USP22 positively modulates ERα action via its deubiquitinase activity in breast cancer.

Authors:  Shengli Wang; Xinping Zhong; Chunyu Wang; Hao Luo; Lin Lin; Hongmiao Sun; Ge Sun; Kai Zeng; Renlong Zou; Wei Liu; Ning Sun; Huijuan Song; Wensu Liu; Qiang Zhang; Zhixuan Liao; Xiaochun Teng; Tingting Zhou; Xun Sun; Yue Zhao
Journal:  Cell Death Differ       Date:  2020-06-03       Impact factor: 15.828

2.  Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer.

Authors:  Jayeon Kim; Volkan Turan; Kutluk Oktay
Journal:  J Clin Endocrinol Metab       Date:  2016-01-11       Impact factor: 5.958

3.  An agonist antibody that blocks autoimmunity by inducing anti-inflammatory macrophages.

Authors:  Kyung Ho Han; Rosana Gonzalez-Quintial; Yingjie Peng; Roberto Baccala; Argyrios N Theofilopoulos; Richard A Lerner
Journal:  FASEB J       Date:  2015-10-19       Impact factor: 5.191

4.  Pyk2 deficiency potentiates osteoblast differentiation and mineralizing activity in response to estrogen or raloxifene.

Authors:  Sumana Posritong; Jung Min Hong; Pierre P Eleniste; Patrick W McIntyre; Jennifer L Wu; Evan R Himes; Vruti Patel; Melissa A Kacena; Angela Bruzzaniti
Journal:  Mol Cell Endocrinol       Date:  2018-02-08       Impact factor: 4.102

5.  Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals.

Authors:  J Huang; P Woods; D Normolle; J P Goff; P V Benos; C J Stehle; R A Steinman
Journal:  Breast Cancer Res Treat       Date:  2016-11-16       Impact factor: 4.872

6.  Progesterone impairs Herceptin effect on breast cancer cells.

Authors:  Kamila Kitowska; Agnieszka Kowalska; Magdalena Mieszkowska; Dominika Piasecka; Andrzej C Skladanowski; Hanna M Romanska; Rafal Sadej
Journal:  Oncol Lett       Date:  2017-11-27       Impact factor: 2.967

7.  RNF144A functions as a tumor suppressor in breast cancer through ubiquitin ligase activity-dependent regulation of stability and oncogenic functions of HSPA2.

Authors:  Yin-Long Yang; Ye Zhang; Dou-Dou Li; Fang-Lin Zhang; Hong-Yi Liu; Xiao-Hong Liao; Hong-Yan Xie; Qin Lu; Lin Zhang; Qi Hong; Wen-Jie Dong; Da-Qiang Li; Zhi-Min Shao
Journal:  Cell Death Differ       Date:  2019-08-13       Impact factor: 15.828

8.  Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer.

Authors:  Shalini Jain; Xiao Wang; Chia-Chi Chang; Catherine Ibarra-Drendall; Hai Wang; Qingling Zhang; Samuel W Brady; Ping Li; Hong Zhao; Jessica Dobbs; Matt Kyrish; Tomasz S Tkaczyk; Adrian Ambrose; Christopher Sistrunk; Banu K Arun; Rebecca Richards-Kortum; Wei Jia; Victoria L Seewaldt; Dihua Yu
Journal:  Cancer Res       Date:  2015-09-17       Impact factor: 12.701

9.  Mathematical models of the transitions between endocrine therapy responsive and resistant states in breast cancer.

Authors:  Chun Chen; William T Baumann; Jianhua Xing; Lingling Xu; Robert Clarke; John J Tyson
Journal:  J R Soc Interface       Date:  2014-05-07       Impact factor: 4.118

10.  A kinetic model identifies phosphorylated estrogen receptor-α (ERα) as a critical regulator of ERα dynamics in breast cancer.

Authors:  Dan Tian; Natalia M Solodin; Prashant Rajbhandari; Kelsi Bjorklund; Elaine T Alarid; Pamela K Kreeger
Journal:  FASEB J       Date:  2015-02-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.